Log in to search using one of your social media accounts:

 

From the heart: The tale of a three-time transplant recipient
Playing youth hockey and Little League in the spring of 1988, I started to become easily fatigued. I became very weak and could no longer run around. By May, a visit to my pediatrician resulted in a trip to the Boston Children’s Hospital Cardiology Clinic on Fegan 6 and the first of many cardiac catheterizations I would receive in my life. The results of that first procedure were shared in my corner room across from the nurses’ station on 6 East (the cardiac step-down at the time): I would need a heart transplant for cardiomyopathy. It was Friday the 13th. I was 10 years old. Tim, before he ...
Source: Thrive, Children's Hospital Boston - February 7, 2018 Category: Pediatrics Authors: Tim Gallagher Tags: Our Patients’ Stories cardiac catheterization cardiomyopathy heart transplant Heart transplant program kidney transplant Pediatric Transplant Center (PTC) Source Type: news

Allergan talks taxes and competition in 2018 outlook
Allergan (NYSE:AGN) had a busy, and occasionally fraught, 2017. After the company inked a controversial deal with a Native American tribe to shield its Restasis patents from review, a federal judge in Texas invalidated the IP, helping to clear the way for generics. And just last week, Allergan announced that it would slash 1,400 jobs in an effort to cut costs. But looking ahead to the new year, chairman and chief executive Brent Saunders seems optimistic. Get the full story at our sister site, Drug Delivery Business News. The post Allergan talks taxes and competition in 2018 outlook appeared first ...
Source: Mass Device - January 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Source Type: news

Facing competition for Restasis, Allergan moves to cut costs by slashing 1,400 jobs
Allergan (NYSE:AGN) said this week that it plans to cut more than 5% of its workforce in an attempt to cut costs. The drug-maker is facing competition from up-coming generics to its dry-eye drug, Restasis. The company said it anticipates taking a $125 million hit from the job cuts, the majority of which will be noted in the fourth quarter of the 2017 fiscal year. Get the full story at our sister site, Drug Delivery Business News. The post Facing competition for Restasis, Allergan moves to cut costs by slashing 1,400 jobs appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Source Type: news

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries
(The Dartmouth Institute for Health Policy& Clinical Practice) Restasis, a blockbuster drug sold by Allergan to treat chronic dry eye, has done $8.8 billion in US sales between 2009 and 2015, including over $2.9 billion in public monies through Medicare Part D. In an article in JAMA Internal Medicine, 'A Clear-Eyed View of Restasis and Chronic Dry Eye Disease,' Dartmouth physician-researchers Lisa Schwartz and Steven Woloshin argue that a more fundamental question we should be asking is: does Restasis even work? (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 2, 2018 Category: International Medicine & Public Health Source Type: news

Comprehensive computational design of ordered peptide macrocycles
Mixed-chirality peptide macrocycles such as cyclosporine are among the most potent therapeutics identified to date, but there is currently no way to systematically search the structural space spanned by such compounds. Natural proteins do not provide a useful guide: Peptide macrocycles lack regular secondary structures and hydrophobic cores, and can contain local structures not accessible with l-amino acids. Here, we enumerate the stable structures that can be adopted by macrocyclic peptides composed of l- and d-amino acids by near-exhaustive backbone sampling followed by sequence design and energy landscape calculations. ...
Source: ScienceNOW - December 14, 2017 Category: Science Authors: Hosseinzadeh, P., Bhardwaj, G., Mulligan, V. K., Shortridge, M. D., Craven, T. W., Pardo-Avila, F., Rettie, S. A., Kim, D. E., Silva, D.-A., Ibrahim, Y. M., Webb, I. K., Cort, J. R., Adkins, J. N., Varani, G., Baker, D. Tags: Biochemistry reports Source Type: news

Restasis buyers level antitrust lawsuit against Allergan
A proposed class of Restasis buyers filed an antitrust suit last week in a Texas federal court against Allergan (NYSE:AGN), according to reports from Law360. The suit accuses Allergan of blocking generics to its dry-eye drug using tactics like sham infringement suits and a controversial deal with a Native American tribe. Get the full story at our sister site, Drug Delivery Business News. The post Restasis buyers level antitrust lawsuit against Allergan appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Allergan Source Type: news

Allergan assuages shareholder fears over losing Restasis patent
(Reuters) - Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan tries to assuage shareholder fears over Restasis
(Reuters) - Allergan Plc on Wednesday tried to reassure shareholders after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis, downplaying the importance of the loss of revenue from the drug. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan beats earnings estimates on strong sales of Botox, Restasis
(Reuters) - Allergan Plc's third-quarter profit topped Wall Street forecasts on Wednesday, as the drugmaker sold more Botox and benefited from strength in its eye care business that houses dry-eye medicine Restasis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

MENTOR Results, New Trial Design Pitches at Kidney Week MENTOR Results, New Trial Design Pitches at Kidney Week
Findings from a randomized comparison of rituximab and cyclosporine for membranous nephropathy will be released here at Kidney Week, along with innovative trial design ideas for the future.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2017 Category: Consumer Health News Tags: Nephrology News Source Type: news

Imprimis to offer low-cost alternative to Restasis for dry eye disease
Imprimis Pharmaceuticals is set to provide its cyclosporine-based formulations as customisable and potential low-cost alternatives to Restasis indicated for dry eye disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 22, 2017 Category: Pharmaceuticals Source Type: news

Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis(R)
Initial prescriptions will be 99 cents for a one month supply with refills starting at $79 per month, including shipping SAN DIEGO, Oct. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmol... Biopharmaceuticals, Ophthalmology, Product Launch Imprimis Pharmaceuticals, Cyclosporine, Restasis, Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 19, 2017 Category: Pharmaceuticals Source Type: news

Imprimis Pharma to take on Allergan's Restasis with cheaper product
(Reuters) - Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan ruling casts doubt on tribal patent strategy
(Reuters) - A U.S. judge ’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Judge in Texas Invalidates Allergan Patents on Restasis U.S. Judge in Texas Invalidates Allergan Patents on Restasis
A U.S. judge invalidated patents on Allergan Plc's dry eye medicine Restasis on the grounds that the patents cover obvious ideas, a decision that drove the pharmaceutical company's shares down more than 6%.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 17, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Mylan: Allergan ’ s legal move with tribe reveals “ duplicitousness ” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came in a suit involving generic drugmakers like Mylan (NSDQ:MYL), which celebrated the ruling as a push back against Allergan’s recent move to transfer its Restasis patents to a Native American tribe. Get the full story at our sister site, Drug Delivery Business News. The post Mylan: All...
Source: Mass Device - October 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news

Patents For Restasis Are Invalidated, Opening Door to Generics
The ruling, by a federal judge in Texas, is a setback for Allergan, which had transferred the patents to a Mohawk tribe in order to protect them. (Source: NYT Health)
Source: NYT Health - October 16, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Inventions and Patents Drugs (Pharmaceuticals) Generic Brands and Products Allergan Inc Patent and Trademark Office (US) Source Type: news

Texas judge rules Allergan ’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today. The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA). Get the full story at our sister site, Drug Delivery Business News. The post Texas judge rules Allergan’s Restasis patents invalid appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Teva Pharmaceuticals Source Type: news

U.S. judge in Texas invalidates Allergan patents on Restasis
(Reuters) - Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

MassDevice.com +5 | The top 5 medtech stories for October 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. 10 tips for selecting and managing a medtech development partner There many things to consider when searching for and interacting with a product development firm – and the stakes are high! Most early-stage medical device ...
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Allergan settles Restasis patent challenge after moving patents to Native American tribe
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in federal court. Get the full story at our sister site, Drug Delivery Business News. The post Allergan settles Restasis patent challenge after moving patents to Native American tr...
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Akorn Allergan Inc. innopharma Mylan Teva Pharmaceuticals Source Type: news

Allergan settles with one of four companies contesting Restasis patent
(Reuters) - Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute
Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Mylan says Allergan misusing tribal sovereignty in patent dispute
NEW YORK (Reuters) - Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis. (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan pays Mohawk Tribe to protect patents from challenges
(Reuters) - Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. (Source: Reuters: Health)
Source: Reuters: Health - September 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Shire applies for European approval of potential blockbuster eye drop
One of the state ’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016 . It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2017 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Gengraf Capsules (Cyclosporine Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 11, 2017 Category: Drugs & Pharmacology Source Type: news

Allergan, Argentum settle patent dispute over eye drug Restasis
(Reuters) - U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis. (Source: Reuters: Health)
Source: Reuters: Health - April 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
DUBLIN, March 22, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) today announced the availability of RESTASIS MULTIDOSE™, which is the same preservative-free RESTASIS® formulation, but now offered in a multidose bottle. RESTASIS&... Biopharmaceuticals, Ophthalmology, Product Launch Allergan, RESTASIS, Cyclosporine, Chronic Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

Disseminated Nocardia farcinica Infection in a Patient with Steroid-dependent Autoimmune Hemolytic Anemia: Case Report and Literature Review
We describe a 64-year-old female with autoimmune hemolytic anemia (AIHA) who was steroid dependent and on cyclosporine immunosuppressive therapy. Nocardia farcinica was recovered from the patient's bronchoalveolar lavage (BAL) specimen and several blood cultures. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - January 20, 2017 Category: Microbiology Authors: Zeti Norfidiyati Ayub, Habsah Hasan, Mohd Zulfakar Mazlan, Alwi Muhd Besari Tags: Case Report Source Type: news

Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab
Long-term outcomes of patients with steroid-refractory acute severe ulcerative colitis (UC) are similar whether treated with cyclosporine or infliximab, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Mylan, Allergan launch fight over Restasis eye drop patents
Allergan (NYSE:AGN) said this week that it will “vigorously defend” the patents for its Restasis eye drops, after the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board agreed to an inter partes review of 6 patents as requested by generic competitor Mylan (NSDQ:MYL). The patents are valid until August 2024. “Allergan is disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that protect Restasis,” the company wrote in a statement yesterday. “Allergan is currently reviewing the grounds for the decision to institute, and will continu...
Source: Mass Device - December 9, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news

Gengraf Oral Solution (Cyclosporine Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Neoral (Cyclosporine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Allergan asks FDA to approve Oculeve neurostim device
Allergan (NYSE:AGN) said today that it filed a de novo approval application with the FDA for its Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. The de novo protocol is for low- to moderate-risk devices that don’t have a “substantially equivalent predecessor” device already on the market. “The Oculeve intranasal tear neurostimulator is an exciting potential option ...
Source: Mass Device - July 18, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Optical/Ophthalmic Regulatory/Compliance Allergan Inc. Oculeve Source Type: news

Cyclosporine of No Benefit in Cardiac Arrest (CME/CE)
(MedPage Today) -- Drug failed to improve outcomes in nonshockable patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 15, 2016 Category: Cardiology Source Type: news

Disheartening result for cyclosporine A in nonshockable cardiac arrest
Administering cyclosporine A at the time of resuscitation of patients with nonshockable out-of-hospital cardiac arrest does not reduce the likelihood of subsequent multiple organ failure, shows the results of the CYRUS trial. (Source: MedWire News)
Source: MedWire News - July 15, 2016 Category: Consumer Health News Tags: Cardiology Source Type: news

Persian Gulf War Veterans Still Suffering Serious Health Problems
This year marks the 25th anniversary of the Persian Gulf War. It was fought in late 1990 through early 1991 by a U.S.-led coalition of 34 countries against Iraq in response to Saddam Hussein's invasion of Kuwait. It also was the first U.S. war to be waged after the advent of the 24-hour cable television news cycle. The conflict was accompanied by memorably intense and round-the-clock coverage on CNN. But there've been few recognitions of the war's 25-year milestone on the cable news networks, let alone in broadcast or print media. For David Winnett, a Gulf War combat veteran who climbed the ranks from private to capta...
Source: Healthy Living - The Huffington Post - June 21, 2016 Category: Consumer Health News Source Type: news

Three decades beat as one: 30 years of heart transplants
Tina Medina and her son Luke Tina Medina was not a sickly child, yet she grew up knowing something was physically wrong. She had difficulty keeping up with the other kids in her sixth-grade class and couldn’t run without becoming breathless. Local physicians near her home in Moriah, New York, shrugged it off as asthma — until Tina’s heart stopped twice during a routine appendectomy. “I was told I had a severe heart condition and needed to see a cardiologist right away,” she says. At 15, Tina was diagnosed with restrictive cardiomyopathy, a rare type of cardiomyopathy that causes the heart...
Source: Thrive, Children's Hospital Boston - June 13, 2016 Category: Pediatrics Authors: Emily Williams Tags: Diseases & Conditions Our Patients’ Stories Research and Innovation cardiac surgery cardiomyopathy congential heart defect Department of Cardiac Surgery Dr. Elizabeth Blume Dr. John Mayer ECMO Heart Center heart transplant Heart Source Type: news

Allergan’s Oculeve on track for FDA submission this year
Allergan (NYSE:AGN) said today that it’s on track for an FDA submission this year for the Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. Today the company said a pair of pivotal trials passed their safety and efficacy endpoints, clearing the way for a pre-market approval submission in the 2nd half of the year. The 48-patient OCUN-009 trial evaluated intra- and e...
Source: Mass Device - May 16, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Allergan Inc. Oculeve Source Type: news

Cyclosporine Capsules (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 11, 2016 Category: Drugs & Pharmacology Source Type: news

Allergan Receives Complete Response Letter from FDA for Prior Approval Supplement for RESTASIS(R) (Cyclosporine Ophthalmic Emulsion) 0.05% Multi-Dose Preservative-Free Bottle
DUBLIN, March 10, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) announced today it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Prior Approval Supplement (PAS) for RESTASIS® (C... Biopharmaceuticals, Ophthalmology, FDAAllergan, RESTASIS, Cyclosporine, Chronic Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 10, 2016 Category: Pharmaceuticals Source Type: news

Infliximab May Top Cyclosporine for Steroid-Refractory Ulcerative ColitisInfliximab May Top Cyclosporine for Steroid-Refractory Ulcerative Colitis
Infliximab may be slightly better than cyclosporine for treating patients with steroid-refractory ulcerative colitis (UC), according to results from a systematic review and meta-analysis. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 1, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Nulojix Ups Survival in Kidney Transplant Patient (CME/CE)
(MedPage Today) -- Long-term risk of death, graft loss lower than with cyclosporine (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 27, 2016 Category: Surgery Source Type: news

Cyclosporine A Flops for PCI Cardioprotection (CME/CE)
(MedPage Today) -- Pharmacological post-conditioning suffers a blow (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 25, 2016 Category: Cardiology Source Type: news

HIV-1 Capsid Stabilization Assay
The stability of the HIV-1 core in the cytoplasm is crucial for productive HIV-1 infection. Mutations that stabilize or destabilize the core showed defects in HIV-1 reverse transcription and infection. We developed a novel and simple assay to measure stability of in vitro-assembled HIV-1 CA-NC complexes. This assay allowed us to demonstrate that cytosolic extracts strongly stabilize the HIV-1 core (Fricke et al., J Virol 87:10587–10597, 2013). By using our novel assay, one can measure the ability of different drugs to modulate the stability of in vitro-assembled HIV-1 CA-NC complexes, such as PF74, CAP-1, IXN-053, cy...
Source: Springer protocols feed by Immunology - December 7, 2015 Category: Allergy & Immunology Source Type: news

Scientists identify potential birth control 'pill' for men
Two drugs that help suppress the immune system in organ transplant patients may have a future as the long-sought birth control "pill" for men, new research suggests. The drugs – cyclosporine A (also known as CsA) and FK506 (also known as tacrolimus) – are given to transplant recipients to reduce... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - October 1, 2015 Category: Science Authors: Karen Kaplan Source Type: news

The Cardiology Show From ESC 2015 with Dr Valentin FusterThe Cardiology Show From ESC 2015 with Dr Valentin Fuster
The panel discuss a leadless pacemaker, cyclosporine and reperfusion injury, hypertension treatments, high-sensitivity troponin for early MI diagnosis, and yet more data on antithrombins for PCI. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 2, 2015 Category: Cardiology Tags: Cardiology Roundtable Source Type: news